Drug Profile


Alternative Names: Apilimod mesylate; STA-5326; STA-5326 mesylate

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Madrigal Pharmaceuticals; Synta Pharmaceuticals
  • Class Antirheumatics; Hydrazines; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rheumatoid arthritis
  • Discontinued Common variable immunodeficiency; Crohn's disease; Psoriasis

Most Recent Events

  • 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called as Madrigal Pharmaceuticals
  • 09 Oct 2008 Apilimod is still in phase II trials for Crohn's disease in USA and rheumatoid arthritis in Netherlands
  • 01 Mar 2007 Apilimod is still in phase II trials for Crohn's disease and common variable immunodeficiency in USA and rheumatoid arthritis in Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top